XASE · Healthcare · Biotechnology
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.44 | -0.29 | +34.09% | $0 | ✅ Beat | +1.07% | +2.52% | — |
| 2026-03-30 | Q4 2025 | -0.26 | -3.72 | -1330.77% | $0 | ❌ Miss | +2.07% | -8.03% | -3.52% |
| 2025-11-14 |
| Q3 2025 |
| -0.43 |
| -0.39 |
| +9.30% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.35 | -0.60 | -71.43% | $0 | ❌ Miss | +0.10% | +6.07% | +12.30% |
| 2025-03-24 | Q4 2024 | — | 3.75 | — | $0 | — | -7.28% | -19.94% | -39.22% |
| 2024-11-13 | Q3 2024 | -11.52 | -11.52 | +0.00% | $0 | ➖ Inline | -11.35% | -18.33% | -2.33% |
| 2024-08-12 | Q2 2024 | -13.68 | -11.52 | +15.79% | $0 | ✅ Beat | -0.98% | +0.02% | -21.75% |
| 2024-05-14 | Q1 2024 | -28.08 | -228.24 | -712.82% | $0 | ❌ Miss | -3.07% | +1.23% | -16.56% |
Showing last 8 quarters.